Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14557)	2/11/1998 12:05:00 AM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

Henry, Paclitaxel(Taxol) is indeed a very harsh treatment. It is indicated I believe for metastatic carcinoma of the ovary, but has many unlabeled uses. This drug causes neutropenia, leukopenia, and anemia in over 90% of patients. The incidence of a hypersensitive reaction is 41%. 59% are adversely affected by nausea and vomiting, 43% with diarrhea. 82% suffer from alopecia. It must be administered IV. Now if Ligand has a product that is oral(patient would not have to endure another chemo treatment), has even a decent side affect profile, and shows adequate efficacy, which drug do we think the oncologist will choose? This could be such a relief for these patients!! RXGOLF